(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.
1. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
2. A method for selectively inhibiting PI3Kδ activity, comprising contacting the PI3Kδ with the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
3. A method for treating or ameliorating one or more symptoms of a PI3Kδ-mediated disorder, disease, or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .
4. A method of treating a PI3Kδ-mediated cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , wherein the PI3Kδ-mediated cancer is a hematological cancer.
6. The method of claim 5 , wherein the hematological cancer is a non-Hodgkin's lymphoma.
7. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 , and a pharmaceutically acceptable excipient.
8. The pharmaceutical composition of claim 7 , wherein the composition is formulated as an oral dosage form.
9. The pharmaceutical composition of claim 8 , wherein the oral dosage form is a tablet or capsule.